{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:40:41Z","timestamp":1787067641160,"version":"build-2736575974"},"reference-count":70,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T00:00:00Z","timestamp":1648512000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To explore whether the rectal distension-mediated technique, harnessing human physiology to achieve intrafractional prostate motion mitigation, enables urethra sparing by inverse dose painting, thus promoting dose escalation with extreme hypofractionated stereotactic ablative radiotherapy (SABR) in prostate cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>\n                      Between June 2013 and December 2018, 444 patients received 5 \u00d7 9 Gy SABR over 5 consecutive days. Rectal distension-mediated SABR was employed\n                      <jats:italic>via<\/jats:italic>\n                      insertion of a 150-cm\n                      <jats:sup>3<\/jats:sup>\n                      air-inflated endorectal balloon. A Foley catheter loaded with 3 beacon transponders was used for urethra visualization and online tracking. MRI-based planning using Volumetric Modulated Arc Therapy - Image Guided Radiotherapy (VMAT-IGRT) with inverse dose painting was employed in delivering the planning target volume (PTV) dose and in sculpting exposure of organs at risk (OARs). A 2-mm margin was used for PTV expansion, reduced to 0\u00a0mm at the interface with critical OARs. All plans fulfilled D\n                      <jats:sub>mean<\/jats:sub>\n                      \u226545 Gy. Target motion \u22652 mm\/5 s motions mandated treatment interruption and target realignment prior to completion of the planned dose delivery.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Patient compliance to the rectal distension-mediated immobilization protocol was excellent, achieving reproducible daily prostate localization at a patient-specific retropubic niche. Online tracking recorded \u22641-mm intrafractional target deviations in 95% of treatment sessions, while target realignment in \u22652-mm deviations enabled treatment completion as scheduled in all cases. The cumulative incidence rates of late grade \u22652 genitourinary (GU) and gastrointestinal (GI) toxicities were 5.3% and 1.1%, respectively. The favorable toxicity profile was corroborated by patient-reported quality of life (QOL) outcomes. Median prostate-specific antigen (PSA) nadir by 5 years was 0.19 ng\/ml. The cumulative incidence rate of biochemical failure using the Phoenix definition was 2%, 16.6%, and 27.2% for the combined low\/favorable\u2013intermediate, unfavorable intermediate, and high-risk categories, respectively. Patients with a PSA failure underwent a\n                      <jats:sup>68<\/jats:sup>\n                      Ga-labeled prostate-specific membrane antigen (\n                      <jats:sup>68<\/jats:sup>\n                      Ga-PSMA) scan showing a 20.2% cumulative incidence of intraprostatic relapses in biopsy International Society of Urological Pathology (ISUP) grade \u22653.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The rectal distension-mediated technique is feasible and well tolerated. Dose escalation to 45 Gy with urethra-sparing results in excellent toxicity profiles and PSA relapse rates similar to those reported by other dose-escalated regimens. The existence of intraprostatic recurrences in patients with high-risk features confirms the notion of a high \u03b1\/\u03b2 ratio in these phenotypes resulting in diminished effectiveness with hypofractionated dose escalation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2022.863655","type":"journal-article","created":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T01:27:47Z","timestamp":1648603667000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Urethra Sparing With Target Motion Mitigation in Dose-Escalated Extreme Hypofractionated Prostate Cancer Radiotherapy: 7-Year Results From a Phase II Study"],"prefix":"10.3389","volume":"12","author":[{"given":"Carlo","family":"Greco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oriol","family":"Pares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuno","family":"Pimentel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasco","family":"Louro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justyna","family":"Kociolek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joep","family":"Stroom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Vieira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalila","family":"Mateus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Joao","family":"Cardoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Soares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joao","family":"Marques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elda","family":"Freitas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gra\u00e7a","family":"Coelho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zvi","family":"Fuks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(02)02857-2","article-title":"Leibel S a. High-Dose Intensity Modulated Radiation Therapy for Prostate Cancer: Early Toxicity and Biochemical Outcome in 772 Patients","volume":"53","author":"Zelefsky","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2007.12.030","article-title":"Long-Term Outcome Following Three-Dimensional Conformal\/Intensity-Modulated External-Beam Radiotherapy for Clinical Stage T3 Prostate Cancer","volume":"53","author":"Zelefsky","year":"2008","journal-title":"Eur Urol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.ijrobp.2007.09.020","article-title":"Effect of Increasing Radiation Doses on Local and Distant Failures in Patients With Localized Prostate Cancer","volume":"71","author":"Kupelian","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2019.03.012","article-title":"Dose-Escalated Intensity Modulated Radiation Therapy for Prostate Cancer: 15-Year Outcomes Data","volume":"4","author":"Weg","year":"2019","journal-title":"Adv Radiat Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(98)00438-6","article-title":"Fractionation and Protraction for Radiotherapy of Prostate Carcinoma","volume":"43","author":"Brenner","year":"1999","journal-title":"Int J nsof Radiat Oncol Biol Phys"},{"key":"B6","doi-asserted-by":"publisher","first-page":"395","DOI":"10.2307\/3577512","article-title":"Contrarian Concepts in the Progress of Radiotherapy","volume":"119","author":"Withers","year":"2006","journal-title":"Radiat Res"},{"key":"B7","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.ijrobp.2009.10.008","article-title":"Confirmation of a Low \u03b1\/\u03b2 Ratio for Prostate Cancer Treated by External Beam Radiation Therapy Alone Using a Post-Treatment Repeated-Measures Model for PSA Dynamics","volume":"79","author":"Proust-Lima","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3109\/0284186X.2012.719635","article-title":"Prostate Alpha\/Beta Revisited an Analysis of Clinical Results From 14 168 Patients","volume":"51","author":"Dasu","year":"2012","journal-title":"Acta Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2010.10.075","article-title":"Dose-Fractionation Sensitivity of Prostate Cancer Deduced From Radiotherapy Outcomes of 5,969 Patients in Seven International Institutional Datasets: \u03b1\/\u03b2 = 1.4 (0.9-2.2) Gy","volume":"82","author":"Miralbell","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2017.12.011","article-title":"Dose Response and Fractionation Sensitivity of Prostate Cancer After External Beam Radiation Therapy: A Meta-Analysis of Randomized Trials","volume":"100","author":"Vogelius","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1259\/bjr.20150957","article-title":"Alpha\/beta (a\/B) Ratio for Prostate Cancer Derived From External Beam Radiotherapy and Brachytherapy Boost","volume":"89","author":"Boonstra","year":"2016","journal-title":"Br J Radiol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2018.1433874","article-title":"Clinical Estimation of \u03b1\/\u03b2 Values for Prostate Cancer From Isoeffective Phase III Randomized Trials With Moderately Hypofractionated Radiotherapy","volume":"57","author":"Datta","year":"2018","journal-title":"Acta Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.ijrobp.2020.01.010","article-title":"Diminishing Returns From Ultrahypofractionated Radiation Therapy for Prostate Cancer","volume":"107","author":"Vogelius","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B14","article-title":"Is the \u03b1\/\u03b2 Ratio for Prostate Tumours Really Low and Does It Vary With the Level of Risk at Diagnosis","volume":"33","author":"Fowler","year":"2013","journal-title":"Anticancer Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30102-4","article-title":"Conventional Versus Hypofractionated High-Dose Intensity-Modulated Radiotherapy for Prostate Cancer: 5-Year Outcomes of the Randomised, Non-Inferiority, Phase 3 CHHiP Trial","volume":"17","author":"Dearnaley","year":"2016","journal-title":"Lancet Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30070-5","article-title":"Hypofractionated Versus Conventionally Fractionated Radiotherapy for Patients With Localised Prostate Cancer (HYPRO): Final Efficacy Results From a Randomised, Multicentre, Open-Label, Phase 3 Trial","volume":"17","author":"Incrocci","year":"2016","journal-title":"Lancet Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/jco.2016.34.2_suppl.1","article-title":"NRG Oncology RTOG 0415: A Randomized Phase III Non-Inferiority Study Comparing Two Fractionation Schedules in Patients With Low-Risk Prostate Cancer","volume":"34","author":"Lee","year":"2017","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.71.7397","article-title":"Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer","volume":"35","author":"Catton","year":"2017","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2016.09.049","article-title":"Extreme Hypofractionation Versus Conventionally Fractionated Radiotherapy for Intermediate Risk Prostate Cancer: Early Toxicity Results From the Scandinavian Randomized Phase III Trial \u201cHYPO-RT-PC.\u201d","volume":"96","author":"Widmark","year":"2016","journal-title":"Int J Radiat OncolBiolPhysics"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e188006","DOI":"10.1001\/jamanetworkopen.2018.8006","article-title":"Long-Term Outcomes of Stereotactic Body Radiotherapy for Low-Risk and Intermediate-Risk Prostate Cancer","volume":"2","author":"Kishan","year":"2019","journal-title":"JAMA Network Open"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2013.08.030","article-title":"Stereotactic Body Radiotherapy for Localized Prostate Cancer: Pooled Analysis From a Multi-Institutional Consortium of Prospective Phase II Trials","volume":"109","author":"King","year":"2013","journal-title":"Radiother Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2019.03.051","article-title":"Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Systematic Review and Meta-Analysis of Over 6,000 Patients Treated On Prospective Studies","volume":"104","author":"Jackson","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B23","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s00066-020-01723-8","article-title":"Ultrahypofractionation of Localized Prostate Cancer: Statement From the DEGRO Working Group Prostate Cancer","volume":"197","author":"Wolf","year":"2021","journal-title":"Strahlentherapie und Onkologie"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2020.09.053","article-title":"Dose\u2013response With Stereotactic Body Radiotherapy for Prostate Cancer: A Multi-Institutional Analysis of Prostate-Specific Antigen Kinetics and Biochemical Control","volume":"154","author":"Levin-Epstein","year":"2021","journal-title":"Radiother Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2021.02.008","article-title":"Predictors for Post-Treatment Biopsy Outcomes After Prostate Stereotactic Body Radiotherapy","volume":"159","author":"Zelefsky","year":"2021","journal-title":"Radiother Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.02.014","article-title":"Stereotactic Body Radiation Therapy for Low and Intermediate Risk Prostate Cancer - Results From a Multi-Institutional Clinical Trial","volume":"59","author":"Hannan","year":"2016","journal-title":"Eur J Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/1754-9485.12152","article-title":"Feasibility of and Rectal Dosimetry Improvement With the Use of SpaceOAR\u00ae Hydrogel for Dose-Escalated Prostate Cancer Radiotherapy","volume":"58","author":"van Gysen","year":"2014","journal-title":"J Med Imaging Radiat Oncol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.urology.2017.11.016","article-title":"Absorbable Hydrogel Spacer Use in Prostate Radiotherapy: A Comprehensive Review of Phase 3 Clinical Trial Published Data","volume":"115","author":"Karsh","year":"2018","journal-title":"Urology"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2021.03.025","article-title":"A Multi-Institutional Phase 2 Trial of High-Dose SAbR for Prostate Cancer Using Rectal Spacer","volume":"111","author":"Folkert","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B30","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ijrobp.2021.06.037","article-title":"Radiation Dose to the Intraprostatic Urethra Correlates Strongly With Urinary Toxicity After Prostate Stereotactic Body Radiation Therapy: A Combined Analysis of 23 Prospective Clinical Trials","volume":"112","author":"Leeman","year":"2021","journal-title":"Int J Radiat Oncol Biol Physics"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1088\/0031-9155\/60\/2\/549","article-title":"Intra-Fraction Motion of the Prostate Is a Random Walk","volume":"60","author":"Ballhausen","year":"2015","journal-title":"Phys Med Biol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2020.01.029","article-title":"Target Motion Mitigation Promotes High-Precision Treatment Planning and Delivery of Extreme Hypofractionated Prostate Cancer Radiotherapy: Results From a Phase II Study","volume":"146","author":"Greco","year":"2020","journal-title":"Radiother Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.0039","article-title":"Safety and Efficacy of Virtual Prostatectomy With Single-Dose Radiotherapy in Patients With Intermediate-Risk Prostate Cancer: Results From the PROSINT Phase 2 Randomized Clinical Trial","volume":"7","author":"Greco","year":"2021","journal-title":"JAMA Oncol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jicru\/ndq025","article-title":"ICRU Report 83: Prescribing, Recording, and Reporting Photon-Beam IMRT","volume":"10","year":"2010","journal-title":"J Int Commission Radiat Units Meas"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2011.05.012","article-title":"Overview of Prostate Anatomy, Histology, and Pathology","volume":"40","author":"Lee","year":"2011","journal-title":"Endocrinol Metab Clin North Am"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(01)01453-5","article-title":"Organ Motion and Its Management","volume":"50","author":"Langen","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(02)03008-0","article-title":"Measurement of Intrafractional Prostate Motion Using Magnetic Resonance Imaging","volume":"54","author":"Mah","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2006.10.026","article-title":"Multi-Institutional Clinical Experience With the Calypso System in Localization and Continuous, Real-Time Monitoring of the Prostate Gland During External Radiotherapy","volume":"67","author":"Kupelian","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2012\/130579","article-title":"Prostate Intrafraction Translation Margins for Real-Time Monitoring and Correction Strategies","volume":"2012","author":"Litzenberg","year":"2012","journal-title":"Prostate Cancer"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2014.10.049","article-title":"Continuous Monitoring and Intrafraction Target Position Correction During Treatment Improves Target Coverage for Patients Undergoing SBRT Prostate Therapy","volume":"91","author":"Lovelock","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2021.05.004","article-title":"Reproducibility and Accuracy of a Target Motion Mitigation Technique for Dose-Escalated Prostate Stereotactic Body Radiotherapy","volume":"160","author":"Greco","year":"2021","journal-title":"Radiother Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2013.05.019","article-title":"The Non-Gaussian Nature of Prostate Motion Based on Real-Time Intrafraction Tracking","volume":"87","author":"Lin","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-007-0159-6","article-title":"Basic Principles of Anatomy for Optimal Surgical Treatment of Prostate Cancer","volume":"25","author":"Walz","year":"2007","journal-title":"World J Urol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2168.2000.01542.x","article-title":"Anatomy of Denonviliers\u2019 Fascia and Pelvic Nerves, Impotence, and Implications for the Colorectal Surgeon","volume":"87","author":"Lindsey","year":"2000","journal-title":"Br J Surg"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1007\/s00276-014-1336-0","article-title":"Denonvilliers\u2019 Fascia Revisited","volume":"37","author":"Kim","year":"2015","journal-title":"Surg Radiol Anat"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-012-2071-1","article-title":"The Physiology of Human Defecation","volume":"57","author":"Palit","year":"2012","journal-title":"Digestive Dis Sci"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-021-00487-5","article-title":"Understanding the Physiology of Human Defaecation and Disorders of Continence and Evacuation","volume":"18","author":"Heitmann","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2011.07.028","article-title":"An Endorectal Balloon Reduces Intrafraction Prostate Motion During Radiotherapy","volume":"83","author":"Smeenk","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2010.08.052","article-title":"Real-Time Study of Prostate Intrafraction Motion During External Beam Radiotherapy With Daily Endorectal Balloon","volume":"81","author":"Both","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B50","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1259\/bjr.20190056","article-title":"Reduced Motion and Improved Rectal Dosimetry Through Endorectal Immobilization for Prostate Stereotactic Body Radiotherapy","volume":"92","author":"de Leon","year":"2019","journal-title":"Br J Radiol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/0031-9384(95)02058-6","article-title":"Rectal Adaptation to Distention: Implications for the Determination of Perception Thresholds","volume":"58","author":"Musial","year":"1995","journal-title":"Physiol Behav"},{"key":"B52","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/BF00496148","article-title":"Rectal Compliance: A Critical Reappraisal","volume":"5","author":"Madoff","year":"1990","journal-title":"Int J Colorectal Dis"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(90)90620-G","article-title":"Sensory and Motor Responses to Rectal Distention Vary According to Rate and Pattern of Balloon Inflation","volume":"99","author":"Sun","year":"1990","journal-title":"Gastroenterology"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/BF00304291","article-title":"The Trigger for Rectal Filling Sensation","volume":"9","author":"Broens","year":"1994","journal-title":"Int J Colorectal Dis"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-018-5201-6","article-title":"Normal Rectal Filling Sensations in Patients With an Enlarged Rectum","volume":"64","author":"Verkuijl","year":"2019","journal-title":"Digestive Dis Sci"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2017.03.006","article-title":"Stereotactic Ablative Radiotherapy in the Treatment of Low and Intermediate Risk Prostate Cancer: Is There an Optimal Dose","volume":"123","author":"Helou","year":"2017","journal-title":"Radiother Oncol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.prro.2016.07.004","article-title":"Receiver Operating Curves and Dose-Volume Analysis of Late Toxicity With Stereotactic Body Radiation Therapy for Prostate Cancer","volume":"7","author":"Zhang","year":"2017","journal-title":"Pract Radiat Oncol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2019.09.006","article-title":"Early Tolerance and Tumor Control Outcomes With High-Dose Ultrahypofractionated Radiation Therapy for Prostate Cancer","volume":"3","author":"Zelefsky","year":"2020","journal-title":"Eur Urol Oncol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1007\/s00066-018-1338-7","article-title":"Phase II Study of Accelerated Linac-Based SBRT in Five Consecutive Fractions for Localized Prostate Cancer","volume":"195","author":"Alongi","year":"2019","journal-title":"Strahlenther Onkol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2019.08.007","article-title":"A Prospective Single-Arm Phase 2 Study of Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy for Prostate Cancer: Early Toxicity Results","volume":"105","author":"Bruynzeel","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2966","article-title":"Once-A-Week or Every-Other-Day Urethra-Sparing Prostate Cancer Stereotactic Body Radiotherapy, a Randomized Phase II Trial: 18 Months Follow-Up Results","volume":"9","author":"Zilli","year":"2020","journal-title":"Cancer Med"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2015.12.010","article-title":"Predictive Parameters of Symptomatic Hematochezia Following 5-Fraction Gantry-Based SABR in Prostate Cancer This Study was Presented in Part at the 29th Canadian Association of Radiation Oncology Annual Scientific Meeting. Kelowna, BC, September 9-12, 201","volume":"94","author":"Musunuru","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2020.09.054","article-title":"Prostate Stereotactic Body Radiation Therapy: An Overview of Toxicity and Dose Response","volume":"110","author":"Wang","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.254623","article-title":"Intraprostatic Tumor Segmentation on PSMA PET Images in Patients With Primary Prostate Cancer With a Convolutional Neural Network","volume":"62","author":"Kostyszyn","year":"2021","journal-title":"J Nucl Med: Off Publication Soc Nucl Med"},{"key":"B65","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13014-018-1036-8","article-title":"Focal Dose Escalation for Prostate Cancer Using 68Ga-HBED-CC PSMA PET\/CT and MRI: A Planning Study Based on Histology Reference","volume":"13","author":"Zamboglou","year":"2018","journal-title":"Radiat Oncol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s13014-018-1047-5","article-title":"PSMA-PET Based Radiotherapy: A Review of Initial Experiences, Survey on Current Practice and Future Perspectives","volume":"13","author":"Zschaeck","year":"2018","journal-title":"Radiat Oncol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02873","article-title":"Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients With Localized Prostate Cancer: Results From the FLAME Randomized Phase III Trial","volume":"39","author":"Kerkmeijer","year":"2021","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.prnil.2018.03.005","article-title":"Prostate Irradiation With Focal Dose Escalation to the Intraprostatic Dominant Nodule: A Systematic Review","volume":"6","author":"Feutren","year":"2018","journal-title":"Prostate Int"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2021.09.004","article-title":"The Journey of Radiotherapy Dose Escalation in High Risk Prostate Cancer; Conventional Dose Escalation to Stereotactic Body Radiotherapy (SBRT) Boost Treatments","volume":"20","author":"Mesci","year":"2021","journal-title":"Clin Genitourinary Cancer"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13225795","article-title":"Psma-Pet\/Mri-Based Focal Dose Escalation in Patients With Primary Prostate Cancer Treated With Stereotactic Body Radiation Therapy (Hypofocal-Sbrt): Study Protocol of a Randomized, Multicentric Phase Iii Trial","volume":"13","author":"Zamboglou","year":"2021","journal-title":"Cancers"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.863655\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T09:57:41Z","timestamp":1648807061000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.863655\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,29]]},"references-count":70,"alternative-id":["10.3389\/fonc.2022.863655"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.863655","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,29]]},"article-number":"863655"}}